Research shows that puberty blockers can prevent the need for top surgery in trans men and non-binary people assigned female at birth, but timing is crucial for this protective effect. When puberty blockers are administered before or during the early stages of puberty, they prevent the development of breast tissue that would otherwise require surgical removal later.
Evidence indicates that the window for this preventive benefit is narrow and requires careful clinical assessment. Puberty blockers need to be started before significant breast development occurs to be effective in avoiding future surgical intervention. Guidelines emphasise that this timing consideration represents one of the key medical arguments for providing access to puberty blockers when clinically appropriate, as early intervention can prevent the need for more invasive procedures during adulthood.
Medical professionals recognise that this preventive approach can significantly impact a young person's future wellbeing and reduce the physical and psychological challenges associated with surgical procedures. Each case requires individual assessment to determine the most appropriate timing and treatment plan, balancing the potential benefits with careful consideration of the young person's overall health and development.